How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85%

Group 1 - Arcutis Biotherapeutics, Inc. (ARQT) shares have increased by 25.7% over the past four weeks, closing at $16.09, with a mean price target of$20.25 indicating a potential upside of 25.9% [1] - The average price targets from analysts range from a low of $15 to a high of$29, with a standard deviation of $3.96, suggesting variability in estimates [2] - Analysts show a consensus that ARQT will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][10] Group 2 - The Zacks Consensus Estimate for ARQT has increased by 50.7% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [11] - ARQT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [12]